COPENHAGEN (Reuters) -Obesity drugmaker Novo Nordisk on Tuesday cut its full-year sales and operating profit forecasts for the second time this year, sending its shares down as much as 17%. The maker of weight-loss drug Wegovy is struggling to convince investors it can remain competitive in the obesity drug boom against U.

The company has looked internally for its new leader, as Doustdar is currently serving as its head of international operations. Jørgensen is stepping down by "mutual agreement" with Novo Nordisk's board in the wake of steep falls in its share price and pressure from the Novo Nordisk Foundation, which has a controlling interest in the drugmaker.